|
|
 |
|
|
 Printer Friendly
|
|
|
|
          |
|
|
|
|
|
| IBCSG 22-00 : Maintenance Chemotherapy |
|
|
|
Trial Status: | Open to patient entry |
|
|
|
|
Treatment type: | Chemotherapy |
|
|
|
|
Stage of Disease: | Early |
|
|
|
|
Intent of Treatment: | Anticancer |
|
|
|
|
|
|
|
Title: |
|
|
| Low dose cytotoxics as anti-angiogenesis treatment following adjuvant induction chemotherapy for patients with ER-Negative and PgR negative breast cancer. |
|
|
|
|
|
Summary: |
|
|
| The standard of care for some types of breast cancer is to have no further treatment following the standard initial chemotherapy. This study will evaluate the effectiveness of an additional year of low dose chemotherapy following standard chemotherapy. 900 patients at many centres around the world will be randomly assigned (similar to the toss of a coin) to receive either 12 months of oral low dose maintenance chemotherapy after they complete standard chemotherapy or to have no further treatment. This study will find out whether oral low dose maintenance chemotherapy reduces the risk of disease recurrence. |
|
|
|
|
|
Coordinating Group: |
|
|
Australia and New Zealand:
- ANZ Breast Cancer Trials Group (ANZ BCTG)
International:
- International Breast Cancer Study Group (IBCSG)
For more information:
Women who are interested in taking part in a clinical trial should discuss this with their doctor. In addition, please view links to other websites that provide information about clinical trial participation. |
|
|
|
|